ArticleJournal of cellular and molecular medicine2021
Serum exosomal lncRNA XIST is a potential non-invasive biomarker to diagnose recurrence of triple-negative breast cancer.
Article in Journal of cellular and molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Exosomes and Triple-Negative Breast Cancer: Current Knowledge and Clinical Significance.International journal of molecular sciences · 2026Pooled it
- Unveiling the functional paradigm of exosome-derived long non-coding RNAs (lncRNAs) in cancer: based on a narrative review and systematic review.Journal of cancer research and clinical oncology · 2023Pooled it
- The Multifaceted Role of Extracellular Vesicles in Triple Negative Breast Cancer.International journal of molecular sciences · 2026Review
- Exploring the functional role of XIST in breast cancer from mechanisms to clinical implications.Discover oncology · 2026Review
- Exosome-derived LncRNAs in bone remodeling: recent advances and future directions for bone disease therapy.Stem cell research & therapy · 2026Review
- Clinical Applications of Blood-Derived Extracellular Vesicle Biomarkers in Breast Cancer: A Scoping Review.International journal of molecular sciences · 2026Article
- Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature.Cell reports. Medicine · 2026Article
- Unlocking the power of non-coding RNAs: toward real-time cancer monitoring in precision oncology.Molecular cancer · 2026Review
- LncRNAs as regulators of chemoresistance and chemosensitivity in triple-negative breast cancer.Genetics and molecular biology · 2026Article
- The role of serum acsl4 in differentiating early-stage breast cancer.European journal of medical research · 2025Observational
- The Role of Long Non-Coding RNAs in Modulating the Immune Microenvironment of Triple-Negative Breast Cancer: Mechanistic Insights and Therapeutic Potential.Biomolecules · 2025Review
- Long Non-Coding RNAs: Key Regulators of Tumor Epithelial/Mesenchymal Plasticity and Cancer Stemness.Cells · 2025Review
- The role of ceRNAs in breast cancer microenvironmental regulation and therapeutic implications.Journal of molecular medicine (Berlin, Germany) · 2025Review
- Diagnostic and Prognostic Significance of Exosomes and Their Components in Patients With Cancers.Cancer medicine · 2025Review
- LINC00892 as a Prognostic Biomarker in Lung Adenocarcinoma: Role in Immune Infiltration and EMT Suppression.Journal of immunology research · 2025Article
- Extracellular vesicles in triple-negative breast cancer: current updates, challenges and future prospects.Frontiers in molecular biosciences · 2025Review
- Predictive Value of Pyroptosis Markers (NLRP3, HMGB1, and Caspase-1) in the Prognosis of Patients With Metastatic Breast Cancer: A Prospective Observational Study.The breast journal · 2025Observational
- Clinical relevance of plasma-derived exosomal long non-coding RNAs (lncRNAs) CCAT1 and XIST in colorectal cancer patients.Molecular biology research communications · 2025Article
- Significance of serum lncRNA XIST in chronic obstructive pulmonary disease and its progression to pulmonary heart disease.BMC pulmonary medicine · 2024Article
- Circulating exosomal PCAT1 as a complement of carcinoembryonic antigen for early colorectal cancer diagnosis.Heliyon · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exosomal lncRNAs secreted by cancer cells can serve as potential biomarkers in the diagnosis and prognosis of various tumours. Here, we are committed to explore the diagnostic and prognostic value of serum exosomal XIST secreted by tumour cells to predict recurrence in patients with triple-negative breast cancer (TNBC). Significant increments in XIST and exo-XIST from tumour tissues and blood serum were found in reoccurring TNBC patients by comparison with non-recurrences. Levels of serum exo-XIST were only significantly increased in TNBC recurrence and no association with other clinicopathological parameters. Additionally, serum exo-XIST levels could be served as an assessment of change in the load of triple-negative breast cancer. Expressions of exo-XIST were markedly decreased after resection of the primary breast tumours and obviously elevated at the time of recurrence. Finally, an obvious association was identified between serum exo-XIST levels and a poorer overall survival (OS) in TNBC patients. Levels of serum exo-XIST may serve as a diagnostic and prognostic biomarker to predict the recurrent TNBC-loading status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.